IFN has been used in the treatment of KMS since 1992 due to its antiproliferative and antiangiogenic effect.[9] In some series, IFN has been recommended as first line therapy The two forms of IFN α 2a and IFN α 2b, are probably identical in efficacy, and both forms have been used in KMS and life- threatening hemangiomas of infancy at a dosage of 3 million IU/m2/day, with favorable results. Here, IFNA1 is linked to hemangioma.